RSV Seasonal Vaccine Introduction and Growth Strategy
Delivering our commitments for attractive medium-term growth
On track with continued organic and business development progress
2021-2026 outlook
Sales
Metric
>5% CAGR
Adj. operating profit
>10% CAGR
Vaccines
Specialty Medicines
General Medicines
High-single-digit % CAGR
Double digit % CAGR
Broadly stable
>30% by 2026
Cash generated from Operations
>£10bn by 2026
Adj. operating margin
On track
Pipeline
Arexvy. US FDA and EMA approved RSV1
vaccine for older adults
MenABCWY: preliminary pivotal phase III
data presented at ESPID2
Shingrix. approved in Japan for at-risk
adults
*413 NgG vaccine candidate for Neisseria
gonorrhoeae: US FDA fast-track
designation
Jemperli. 1L EC3 indication granted
priority review by US FDA
Business Development
Completion of BELLUS Health, Inc.
acquisition and exclusive licensing
agreement with Scynexis, Inc.
GSK
All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q2 2023 earnings release and the 2022 Annual Report.
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. CAGR is for the 5 years to 2026, using 2021 as
the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from
the above. 1. Respiratory syncytial virus 2. European Society For Paediatric Infectious Diseases 3. Endometrial cancer.
6View entire presentation